Literature DB >> 12200394

DNB: a partial D with anti-D frequent in Central Europe.

Franz F Wagner1, Nicole I Eicher, Jan R Jørgensen, Cornelie B Lonicer, Willy A Flegel.   

Abstract

To improve routine D typing and define transfusion strategy, it is important to establish the frequency of partial D alleles and their susceptibility to anti-D alloimmunization due to transfusion or pregnancy. We identified the partial D DNB that was caused by an RHD(G355S) allele associated with a CDe haplotype and whose phenotype presented a normal D in routine typing. The antigen density was about 6000 D antigens per red blood cell, and the Rhesus index was 0.02. Five anti-D immunization events with allo-anti-D titers up to 128 were observed. Twelve carriers of DNB were whites of Central Europe; the only Danish proband had Austrian ancestry. DNB was the most frequent partial D recognized so far in whites, occurring with frequencies of up to 1:292 in Switzerland. DNB was the underlying partial D phenotype in a relevant fraction of anti-D immunizations occurring in whites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200394     DOI: 10.1182/blood-2002-03-0742

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Molecular genetics and clinical applications for RH.

Authors:  Willy A Flegel
Journal:  Transfus Apher Sci       Date:  2011-01-28       Impact factor: 1.764

2.  The genetics of the Rhesus blood group system.

Authors:  Willy A Flegel
Journal:  Blood Transfus       Date:  2007-04       Impact factor: 3.443

Review 3.  The Rhesus Site.

Authors:  Franz F Wagner; Willy A Flegel
Journal:  Transfus Med Hemother       Date:  2014-09-15       Impact factor: 3.747

4.  A simple diagnostic strategy for RhD typing in discrepant cases in the Indian population.

Authors:  Swati Kulkarni; Vasantha Kasiviswanathan; Kanjaksha Ghosh
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

5.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

6.  Application of a Multivariant, Caucasian-Specific, Genotyped Donor Panel for Performance Validation of MDmulticard®, ID-System®, and Scangel® RhD/ABO Serotyping.

Authors:  Christoph Gassner; Esther Rainer; Elfriede Pircher; Lydia Markut; Günther F Körmöczi; Christof Jungbauer; Dietmar Wessin; Roswitha Klinghofer; Harald Schennach; Peter Schwind; Diether Schönitzer
Journal:  Transfus Med Hemother       Date:  2009-05-18       Impact factor: 3.747

7.  Anti-D Antibodies in Pregnant D Variant Antigen Carriers Initially Typed as RhD.

Authors:  Jelena Lukacevic Krstic; Slavica Dajak; Jasna Bingulac-Popovic; Vesna Dogic; Jela Mratinovic-Mikulandra
Journal:  Transfus Med Hemother       Date:  2016-10-14       Impact factor: 3.747

8.  Anti-D reagents should be chosen accordingly to the prevalence of D variants in the obstetric population.

Authors:  Jelena Lukacevic Krstic; Slavica Dajak; Jasna Bingulac-Popovic; Vesna Dogic; Jela Mratinovic-Mikulandra
Journal:  J Clin Lab Anal       Date:  2017-06-26       Impact factor: 2.352

9.  D category IV: a group of clinically relevant and phylogenetically diverse partial D.

Authors:  Inge von Zabern; Franz F Wagner; Joann M Moulds; John J Moulds; Willy A Flegel
Journal:  Transfusion       Date:  2013-03-05       Impact factor: 3.157

10.  Variant RHD Types in Brazilians With Discrepancies in RhD Typing.

Authors:  Fernanda Carolina Alves Campos; Mariza Aparecida Mota; Maria Giselda Aravechia; Kelyan Bertani Torres; Carolina Bonet Bub; José Mauro Kutner; Lilian Castilho
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.